Biotechnology uses living cells to develop or manipulate products for specific purposes, such as transgenic foods. Biotechnology is thus linked to genetic engineering and emerged as a discipline at the beginning of the 20th century in the agri-food industry, which was then joined by other sectors such as medicine or the environment. Consequently, biotechnology is attracting more and more attention from companies and individuals who are becoming increasingly interested in investing in the field.
SummaryWhat is Biotechnology/Bioengineering?5 Biotech Startups to Watch in 2021/22 1. Cerevel Therapeutics 2. Passage Bio3. Kumuda 4. 10x genomics 5. HealingToday, the five branches that divide modern biotechnology – human, environmental, industrial, animal and plant – help us fight disease and hunger, produce safer and cleaner products, reduce our ecological footprint and save energy. energy more efficiently.
This particular type of business is based on the development of advanced technologies in highly qualified professionals with advanced academic and technical qualifications. As a result, companies that engage in bioengineering are increasingly getting noticed because of the advancements they represent. Below is a list of 5 biotech startups to watch closely in 2021/22:
Founded by Pfizer and Bain Capital after their 2018 combination, Cerevel Therapeutics is a clinical-stage biopharmaceutical organization that studies brain biology. Cerevel Therapeutics is dedicated to creating innovative therapies through the use of advanced chemistry and pharmacology, while considering the needs of their community.
Cerevel Therapeutics states that even some of the most recurring neurological diseases lack appropriate therapeutic alternatives, which are not fully effective, difficult to follow, and can cause serious side effects. As a result, Cerevel Therapeutics was founded with the intention of finding the right treatments for life-threatening and devastating neuroscientific diseases that do not yet have a cure, such as epilepsy, schizophrenia and Parkinson's disease.
Despite being a startup in the field, Passage Bio is getting a lot of attention due to its ambition to focus on a specific niche within genetic medicine:to develop effective procedures to treat various rare monogenic diseases of the central nervous system. . Moreover, this biotech company centers every decision it makes on its sick patients.
Passage Bio is on a mission to provide patients with a variety of therapies delivered by AAV, in order to change and improve the lives of their patients, while focusing on rare indicators of the CNS. Passage Bio continues to expand existing and new relationships with patients or advocacy groups. This startup is also rapidly advancing lead product candidates into clinical development, while constantly trying to develop proprietary manufacturing capabilities.
Kumuda is a US-based startup accelerating early small molecule drug discovery. Through its platform, Kumuda has identified a potent inhibitor drug candidate for COVID-19 using artificial intelligence (AI). The inhibitory competitor obstructs the human ACE2 receptor to prevent the entry of the SARS-CoV-2 virus. This startup also targets neurological disorders and other diseases.
Continuous improvements in artificial intelligence are accelerating the start of reduced-particle drugs. AI empowers Kumuda to leverage extensive omics and chemical data for information-driven target discovery. This allows specialists to efficiently scan the chemical space to find lead molecules with the desired properties. Pharmaceutical and biotech startups such as Kumuda are increasingly examining small atom drugs for a wide range of conditions, including overlooked clinical needs.
10x Genomics is an emerging biotechnology company that has shown great promise in the field of gene sequencing technology. The company is based in the United States and recently completed a funding round that increased the value to billions. It is a major player in the field of life sciences and biological technology that will lead current research with the potential to change modern medicine as we know it.
The company has only been around for seven years, but is a major player in genetic sequencing technology that is now routinely used for many types of scientific research. Not only do they design this innovative technology, but they also manufacture it and distribute the tools and equipment to their customers. They primarily serve research centers, biotechnology organizations, academic institutions, and clinical research organizations.
Created in 2020 Curatif is also considered a startup in the biotechnology sector. It is a leader in on-demand public health services and infrastructure development programs in the United States. It performs large-scale rapid tests and vaccines against COVID-19, also provides other essential services.
Curative partners with communities to strengthen public health services with turnkey programs, easy-to-access experiences, and scalable infrastructure, keeping people everywhere safe, healthy, and informed. Co-founder and CEO is Fred Turner, along with a team of physicians, scientists, engineers, and healthcare industry experts.
In early March 2020, the company focused on COVID-19 testing in its development and production of tests in the United States. Curative has more than 13,000 COVID-19 testing and vaccination sites in 18 states and three highly complex CLIA-certified labs.
